A recent independent investigation made the comparison between the amount of harmful substances present in traditional cigarettes and those emitted using the electronic device IQOS by Philip Morris, innovation that heats the tobacco instead of burning it, and they were able to find quite surprising data and results.
The study presented by the researcher Konstantinos Farsalinos, cardiologist of the Onassis Center for Cardiac Surgery (Greece), confirms the reduction of the levels of carbon molecules dangerous to the health of smokers.
Facts About Electronic Cigarettes
The research “shows that the products of heated tobacco emit substantially less toxins compared with a conventional cigarette”, said in an interview the researcher, expert in cardiac smoking and co-author of the report made with his Colleagues from the Arizona College of Health Solutions and the applied research laboratories Skylab-Med.
The laboratory tests were done simulating the consumption of 20 cartridges of “Heets” Tobacco for IQOS and 20 cigarettes Marlboro Red, recognized brands of the tobacco Philip Morris International, resulting in the levels of exposure to substances Cancers showed a reduction of between 81.7 and 97.9%.
The health-damaging carbon molecules present in cigarette smoke would also be present in IQOS, but with reduced levels. The study shows that IQOS has 91.6% less formaldehyde, 84.9% less acetaldehyde, 90.6% less acrolein, 89.0% less propionaldehido and a 95.3% less crotonaldehido.
According to the investigator, the study focused on dangerous substances called carbonyls because they “contribute to a high risk of cancer and are toxic to the respiratory and cardiovascular system. They are not the only toxic, but they are an important group of toxins, “the doctor said.
The findings of the research “are consistent with the manufacturer’s reports, therefore, our study showed that the industry findings previously published are reliable,” Farsalinos pointed out.
Clinical Studies Add Evidence
The results of the independent study are known only a week after the presentation of a clinical investigation on the impact of IQOS on health, and that the tobacco producer Philip Morris presented at the Global Forum of Nicotine 2018, held in Warsaw, Poland, last June.
These trials were conducted for the first time by the industry to measure the biological response of people who changed to IQOS compared to regular smokers.
The study, which lasted six months, tested 984 people divided into two groups in a random manner. The first group (488) continued to smoke cigarettes; While a second group (496) were changed to IQOS, showing a better physical response in five of eight high-risk clinical points associated with heart, lung and respiratory diseases produced by smoking.
“These results are very encouraging,” said Frank Luedicke, PMI’s Global medical Director. “Everything we’ve seen, including these new results, continues to point in the direction of risk reduction.”
The tobacco Philip Morris International has conducted its own studies on IQOS in which the rate of exposure to harmful substances is 90 to 95% lower than that of traditional cigarettes.
To date, PMI has 2,900 patents granted worldwide, and 4,600 pending patent applications. IQOS is marketed in more than 30 countries in the world and entered the Colombian market in 2017.